![](https://investorshub.advfn.com/uicon/146420.png?cb=1620496853)
Thursday, October 27, 2011 11:16:46 AM
Financing and the stock price:
Up until the end of the fiscal year my projections for the burn rate and ATM sales were very much on track. In July when they reported the results (See my mid-year assessment sniped below) things started to diverge. In spite of the fact that they reported ~$5M in revenue from Avid for the first quarter, the ATM continued at a blistering pace…??? Why? I first thought that the additional cost might be associated with the cost of so many additional trial sites. That still may have been a contributing factor. And then ~9% of the company was sold for ~$6.5M…WTF??? The recent discussion on this board about the possible Avid expansion strikes me as very plausible. Management has not spoken about Avid recently, other than upping the revenue projects to ~$10M to $12M. Regardless of the method i.e. increased CMO revenue, Biosimulars, partial sale of Avid; increased revenue/capital is in our future. My guess…6 – 9 months from now.
This is from my mid-year assessment.
“Last quarters operating costs (Burn rate) were approaching ~$8M. With all of the irons that PPHM has in the fire, I cannot see that going down. As a matter of fact I see the potential for the burn rate to go up.
With a burn rate in the $8-9M range for the last quarter I assume that that money was raised in March and April. With an average share price of $2.27 for March and $2.51 for April they could have sold between 3.5M – 4.0M shares. That would leave ~$24M as a cash reserve at the start of this new fiscal year and outstanding shares of about 71.4M to 71.9M.
With an annual burn rate in the range of ~$32M to ~$36M and my projected cash reserve of ~$24M at the start of the year I suspect that the “Going concern” clause will be with us again. What could change that? There could be signed contracts with projected timetables and payment schedules that could impact the clause in a positive way.”
Data from the 10K:
Burn rate for the fourth quarter was $8,961,000
As of 4-30-11 there were 69,837,142 shares outstanding. +1,951,331
In addition, the 10K states: “Number of shares of Common Stock outstanding as of July 8, 2011: 71,069,858”
Cotara:
There is NO doubt in my mind that management will do everything it can to close a deal for Cotara. I speculated on what I thought a deal would be worth in my beginning of the year analysis that I posted in January, sniped below:
My SWAG…Trial cost ($24M to $37M) + Prior development cost ($20M to $30M…???) + Lump sum ($35M to $70M…???) = $79M to $137M
The above was for both the E.U. & USA markets. There are several scenarios that can come into play; including PPHM keeps the USA market for itself and partners E.U. or Partners All…PPHM goes it alone…or nothing…!!!
BAVITUXIMAB (Viral):
In my earlier assessment I did not consider Bavituximab viral beyond the government contract; however I now believe that the viral indication could be licensed before the oncology indications. I think that the plan is to replace peg-interferon in the current HCV cocktail. In 2010 world wide sales for peg-interferon were ~$2.4M…Hmmmmm… ~$1.6M of that was Roche’s…More Hmmmmm…
BAVITUXIMAB (NSCLC):
According to management we should have data from the two trials by mid-year 2012. Will someone start nibbling before then…???
My personal financial plan…I will continue to buy on these dips and continue to sell half of my trading shares on the pops. That allows me to slowly increase my long position with shares at a zero cost basis.
I hate two things…The shorts that are driving this stock down and waiting…!!!
Regards
Golfho
Recent CDMO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Mawson Finland Provides Update on Exploration Activities at Rajapalot • MFL • Aug 21, 2024 9:06 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM